Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03128047 · ClinicalTrials.gov registry record · Phase 1
HUMC 1612: Optune NovoTTF-200A System
A Phase 1 study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03128047: Completed Phase 1 study, sponsored by Hackensack Meridian Health.
NCT03128047 is a Phase 1 study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03128047, a Phase 1 study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the Optune NovoTTF-200A device can be safely used in combination with chemotherapy in pediatric patients with recurrent high-grade glioma and ependemoma.
Primary Outcome
Number of participants receiving treatment with the Optune NovoTTF-200A System with treatment-related adverse events as assessed by CTCAE v4.0.
Interventions
- DEVICE Optune NovoTTF-200A System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-04-06 |
| Est. Completion | 2025-04-05 |
| Phase | Phase 1 |
What the finished NCT03128047 record still lists
NCT03128047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Optune NovoTTF-200A System is the first listed.
NCT03128047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03128047 about?
NCT03128047 is a clinical study titled "HUMC 1612: Optune NovoTTF-200A System". The purpose of this study is to determine if the Optune NovoTTF-200A device can be safely used in combination with chemotherapy in pediatric patients with recurrent high-grade glioma and ependemoma.
What is the current status of trial NCT03128047?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-04-06. Estimated completion is 2025-04-05.
What interventions are being tested in trial NCT03128047?
The interventions under investigation include: Optune NovoTTF-200A System (DEVICE).
Who is sponsoring clinical trial NCT03128047?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03128047's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI